Newborn screening for krabbe leukodystrophy: a review of the clinical and cost effectiveness and guidelines
CADTH
Record ID 32012000657
English
Authors' recommendations:
There was a lack of high-quality evidence regarding the accuracy of tandem mass spectrometry for the detection of Krabbe disease. None of the reviewed guidelines recommended newborn screening for Krabbe disease as a standard procedure. The additional cost of adding Krabbe disease to an existing panel of newborn screening using tandem mass spectrometry was estimated to be $U.S.2.50 per infant tested.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/feb-2012/RC0328%20Newborn%20screening%20for%20Krabbe%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Infant, Newborn
- Neonatal Screening
- Leukodystrophy, Globoid Cell
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.